Table 3.

Background characteristics and clinical courses of 48 reported cases receiving idarucizumab immediately prior to intravenous thrombolysis

Characteristic
Sex category	Women 23, Men 23, NA 2
Age (yr)	Median, 76.5; IQR, 66-84; range, 40-94
Region	Europe 35, East Asia 4, Oceania 8, USA 1
Indication for dabigatran	Atrial fibrillation 33, cardiomyopathy 1, embolic stroke of undetermined sources 1, NA 13
Dosage of dabigatran	150 mg bid 15, 110 mg bid 29, 150 mg qd 1, NA 3
Admission aPTT (sec) (n=42)	Median, 41.3; IQR, 34-58; range, 24.3-84
Post-idarucizumab aPTT (sec) (n=18)	Median, 29.3; IQR, 28-33; range, 24.1-38.5
Admission NIHSS score (n=47)	Median, 9; IQR, 5-12; range, 3-34
Post-treatment NIHSS score (n=44)	Median, 2; IQR, 0-3; range, 0-42 (death)
Combined mechanical thrombectomy	2: One patient died on day 5. [42]* Another recovered to normal. [49]
Post-treatment intracranial hemorrhage	2: One patient developed sICH on day 2 and died on day 4. [38] Another developed sICH with a mRS score of 5 at day 90. [49]
Recurrent ischemic stroke in acute stage	2: Both patients showed early neurological deterioration with discharge mRS scores of 5. [33,38,42]
Systemic embolism in acute stage	1: He developed deep vein thrombosis and bilateral pulmonary embolism and died on day 5. [42]*
Clinical outcome mainly at discharge	Independent (mRS score 0-2) 30, dependent (mRS score 3-5) 14, death 3, NA 1

Based on data from references 32-52 and our case record.

IQR, interquartile range; NA, not applicable; bid, twice a day; qd, once a day; aPTT, activated partial thromboplastin time; NIHSS, National Institutes of Health Stroke Scale; sICH, symptomatic intracranial hemorrhage; mRS, modified Rankin Scale.

^*The same patient from reference. [43]